These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 22892872)

  • 1. Population pharmacokinetic modeling of sepantronium bromide (YM155), a small molecule survivin suppressant, in patients with non-small cell lung cancer, hormone refractory prostate cancer, or unresectable stage III or IV melanoma.
    Aoyama Y; Kaibara A; Takada A; Nishimura T; Katashima M; Sawamoto T
    Invest New Drugs; 2013 Apr; 31(2):443-51. PubMed ID: 22892872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of sepantronium bromide (YM155), a small-molecule suppressor of survivin, in Japanese patients with advanced solid tumors: dose proportionality and influence of renal impairment.
    Aoyama Y; Nishimura T; Sawamoto T; Satoh T; Katashima M; Nakagawa K
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):373-80. PubMed ID: 22806304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.
    Kelly RJ; Thomas A; Rajan A; Chun G; Lopez-Chavez A; Szabo E; Spencer S; Carter CA; Guha U; Khozin S; Poondru S; Van Sant C; Keating A; Steinberg SM; Figg W; Giaccone G
    Ann Oncol; 2013 Oct; 24(10):2601-2606. PubMed ID: 23857959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.
    Tolcher AW; Mita A; Lewis LD; Garrett CR; Till E; Daud AI; Patnaik A; Papadopoulos K; Takimoto C; Bartels P; Keating A; Antonia S
    J Clin Oncol; 2008 Nov; 26(32):5198-203. PubMed ID: 18824702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor efficacy and biodistribution of liposomal sepantronium bromide (YM155), a novel small-molecule survivin suppressant.
    Kawano H; Shakushiro K; Nakata M; Kita A; Maeda A; Watanabe S; Sako K; Oku N
    Eur J Pharm Biopharm; 2014 Sep; 88(1):283-9. PubMed ID: 24993306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma.
    Kudchadkar R; Ernst S; Chmielowski B; Redman BG; Steinberg J; Keating A; Jie F; Chen C; Gonzalez R; Weber J
    Cancer Med; 2015 May; 4(5):643-50. PubMed ID: 25533314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors.
    Satoh T; Okamoto I; Miyazaki M; Morinaga R; Tsuya A; Hasegawa Y; Terashima M; Ueda S; Fukuoka M; Ariyoshi Y; Saito T; Masuda N; Watanabe H; Taguchi T; Kakihara T; Aoyama Y; Hashimoto Y; Nakagawa K
    Clin Cancer Res; 2009 Jun; 15(11):3872-80. PubMed ID: 19470738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formulation design and evaluation of liposomal sepantronium bromide (YM155), a small-molecule survivin suppressant, based on pharmacokinetic modeling and simulation.
    Shakushiro K; Kawano H; Nakata M; Kita A; Maeda A; Watanabe S; Sako K; Oku N
    Pharm Res; 2015 Jan; 32(1):238-47. PubMed ID: 25033765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma.
    Lewis KD; Samlowski W; Ward J; Catlett J; Cranmer L; Kirkwood J; Lawson D; Whitman E; Gonzalez R
    Invest New Drugs; 2011 Feb; 29(1):161-6. PubMed ID: 19830389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma.
    Papadopoulos KP; Lopez-Jimenez J; Smith SE; Steinberg J; Keating A; Sasse C; Jie F; Thyss A
    Leuk Lymphoma; 2016 Aug; 57(8):1848-55. PubMed ID: 26857688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.
    Nakahara T; Kita A; Yamanaka K; Mori M; Amino N; Takeuchi M; Tominaga F; Hatakeyama S; Kinoyama I; Matsuhisa A; Kudoh M; Sasamata M
    Cancer Res; 2007 Sep; 67(17):8014-21. PubMed ID: 17804712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting response to sepantronium bromide (YM155), a survivin suppressant, by PET imaging with [
    Mitsuoka K; Kita A; Murakami Y; Shirasuna K; Noda A; Yamanaka K; Kaneko N; Miyoshi S
    Nucl Med Biol; 2018; 64-65():41-46. PubMed ID: 30041149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer.
    Shimizu T; Nishio K; Sakai K; Okamoto I; Okamoto K; Takeda M; Morishita M; Nakagawa K
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):211-219. PubMed ID: 32638093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiosynthesis, biodistribution and imaging of [11C]YM155, a novel survivin suppressant, in a human prostate tumor-xenograft mouse model.
    Murakami Y; Matsuya T; Kita A; Yamanaka K; Noda A; Mitsuoka K; Nakahara T; Miyoshi S; Nishimura S
    Nucl Med Biol; 2013 Feb; 40(2):221-6. PubMed ID: 23141550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines.
    Iwasa T; Okamoto I; Suzuki M; Nakahara T; Yamanaka K; Hatashita E; Yamada Y; Fukuoka M; Ono K; Nakagawa K
    Clin Cancer Res; 2008 Oct; 14(20):6496-504. PubMed ID: 18927289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer.
    Giaccone G; Zatloukal P; Roubec J; Floor K; Musil J; Kuta M; van Klaveren RJ; Chaudhary S; Gunther A; Shamsili S
    J Clin Oncol; 2009 Sep; 27(27):4481-6. PubMed ID: 19687333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model.
    Nakahara T; Yamanaka K; Hatakeyama S; Kita A; Takeuchi M; Kinoyama I; Matsuhisa A; Nakano K; Shishido T; Koutoku H; Sasamata M
    Anticancer Drugs; 2011 Jun; 22(5):454-62. PubMed ID: 21389848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer.
    Tolcher AW; Quinn DI; Ferrari A; Ahmann F; Giaccone G; Drake T; Keating A; de Bono JS
    Ann Oncol; 2012 Apr; 23(4):968-73. PubMed ID: 21859898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.
    Yamanaka K; Nakahara T; Yamauchi T; Kita A; Takeuchi M; Kiyonaga F; Kaneko N; Sasamata M
    Clin Cancer Res; 2011 Aug; 17(16):5423-31. PubMed ID: 21737502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of differences in the pharmacokinetics of sepantronium bromide (YM155) between US and Japanese patients with advanced solid tumors or non-Hodgkin lymphoma.
    Aoyama Y; Katashima M; Sawamoto T
    Biopharm Drug Dispos; 2013 Mar; 34(2):137-40. PubMed ID: 23138529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.